Clinical Trial

Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy

Name: Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy — clinical trial record (NCT07424677)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EPICS-IV

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-02-13.

Trial Details

NCT Number	NCT07424677
Lead Sponsor	Zydus Therapeutics Inc.
Conditions	Primary Biliary Cholangitis
Enrollment	89 participants
Start Date	2026-06
Primary Completion	2028-07 (estimated)
Study Completion	2028-11 (estimated)
Updated on ClinicalTrials.gov	2026-05-12